纽泰格 reported revenue of ¥0.58B for the period ended 2026-06-30, +18.1% year on year. Net income was ¥-0.02B, a -3.1% net margin on a 12.5% gross margin. The largest revenue line is 汽车悬架系统 at 47% of the total. Free cash flow for the period was ¥-0.08B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.58B | +18.1% |
| Gross profit | ¥0.07B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.02B | -189.7% |
| Gross margin | 12.5% | Net margin -3.1% |
| Revenue Q/Q | +20.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 汽车悬架系统 | ¥0.27B | 46.6% |
| 汽车其他系统 | ¥0.21B | 36.0% |
| 汽车动力系统 | ¥0.06B | 10.0% |
| 其他 | ¥0.03B | 5.1% |
| 其他(补充) | ¥0.01B | 2.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.51B | 87.5% |
| R&D | ¥0.03B | 5.1% |
| SG&A | ¥0.05B | 7.9% |
| Tax & other | ¥-0.00B | -0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥1.95B |
| Total liabilities | ¥0.71B |
| Shareholders' equity | ¥1.24B |
| Equity / assets | 63.5% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.09B |
| Free cash flow | ¥-0.08B |
| Cash conversion (OCF / net income) | -150% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
泓博医药 ・ 荣信文化 ・ 飞沃科技 ・ 盛帮股份 ・ 五洲医疗 ・ 华康洁净 ・ 和顺科技 ・ 瑞泰新材 ・ 普瑞眼科 ・ 宏源药业 ・ 杰创智能 ・ 威尔高
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies